TNFSF4 Antikörper

Produktnummer ABIN2664441

Dieser Maus Monoklonal Antikörper erkennt spezifisch TNFSF4 in FACS. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für TNFSF4 Antikörper (ABIN2664441)

Target: TNFSF4 (Tumor Necrosis Factor (Ligand) Superfamily, Member 4 (TNFSF4))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TNFSF4 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Klon: 11C3-1

Produktdetails anti-TNFSF4 Antikörper

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu TNFSF4

Target: TNFSF4 (Tumor Necrosis Factor (Ligand) Superfamily, Member 4 (TNFSF4))

Andere Bezeichnung: CD252

Hintergrund: OX40 ligand (OX40L) is a 35 kD type II transmembrane protein which belongs to TNF superfamily, also known as gp34, CD252, CD134L or TNFSF4. The OX40 ligand is expressed on activated B cells, activated endothelial cells, mature dendritic cells, activated CTLs, activated mast cells, and airway smooth muscle cells. OX40 ligand interacts with OX40 antigen (CD134) expressed predominantly on activated T cells to regulate T cell proliferation and differentiation, and to enhance immunoglobulin secretion by activated B cells.

Pathways: Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Activated T Cell Proliferation, Cancer Immune Checkpoints